Omega-3 Fatty Acids (EPA / DHA): Cardiometabolic Protection, Inflammation and Membrane Biology

EPA and DHA are long-chain omega-3 fatty acids built into cell membranes. Without regular oily-fish intake, most adults sit at an Omega-3 Index of 4 to 6%, below the protective 8%. At 1 to 2 g/day they support prevention; at 3 to 4 g/day they lower triglycerides pharmacologically. The index is measurable, targetable and re-testable at four months.

Key points

• The Omega-3 Index target is ≥ 8%; most Western adults measure 4 to 6% without regular oily fish.
• 3 to 4 g EPA+DHA daily lowers triglycerides by 20 to 35%, a licensed pharmacological indication.
• REDUCE-IT showed a 25% event reduction with 4 g pure EPA; EPA/DHA blends were neutral in STRENGTH.
• Re-esterified triglyceride (rTG) forms absorb up to ~70% better than ethyl esters; take with the main meal.
• Re-test the Omega-3 Index at 4 months and titrate the dose against the result.

The biochemical result is fully measurable; the cardiovascular benefit is long-term and not subjectively perceptible.

What problem does it solve?

The long-chain omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are structural and functional constituents of cell membranes. They incorporate into membrane phospholipids, regulate membrane fluidity, serve as substrate for the specialised pro-resolving mediators of inflammation (resolvins, protectins, maresins), reduce hepatic VLDL synthesis and therefore triglycerides, and stabilise the myocardium electrophysiologically.

The problem they address is twofold. First, dietary insufficiency: endogenous conversion of plant-derived ALA to EPA/DHA runs below 5 to 10%, so without regular oily-fish intake the Omega-3 Index of most Western populations sits at 4 to 6%, well below the protective threshold of 8%. Second, hypertriglyceridaemia and low-grade chronic inflammation, where omega-3s act pharmacologically at higher doses.

Why does that matter?

A low Omega-3 Index is associated in prospective cohorts with higher cardiovascular and all-cause mortality; the estimated life-expectancy difference between an index below 4% and above 8% is roughly 4 to 5 years (Framingham/Harris), an order of magnitude comparable to smoking. Triglycerides represent an independent residual risk factor even on statin therapy with LDL at target.

For the peri- and postmenopausal woman the issue carries particular weight: the loss of oestrogen is typically accompanied by rising triglycerides, a shift toward small dense LDL particles, increasing visceral adiposity and amplified inflammatory markers. DHA is additionally critical for brain and retina, with epidemiological signals linking low levels to faster cognitive decline.

What evidence supports it?

The field is defined by the REDUCE-IT / STRENGTH divergence, which remains its central interpretive question.

Interpretive note: the REDUCE-IT/STRENGTH divergence is attributed either to the distinct biology of pure EPA (membrane and plaque stabilisation) or to REDUCE-IT's mineral-oil placebo. The practical consequence: where the goal is cardiovascular protection in a high-risk patient, prescription pure EPA has the stronger evidence; where the goal is restoring the Omega-3 Index, a quality EPA+DHA blend suffices. One additional point of vigilance: REDUCE-IT and subsequent meta-analyses record a small increase in atrial fibrillation episodes at doses ≥ 2 to 4 g/day.

Who should use it?

• Individuals with low oily-fish intake (under 2 servings per week), in practice the majority, even in Mediterranean Greece, where actual intake often falls short of the image.
• Hypertriglyceridaemia (TG over 150 mg/dL; pharmacological dosing for TG 200 to 500 mg/dL), particularly within the metabolic syndrome.
• Secondary cardiovascular prevention on statin therapy with residual TG 135 to 499 mg/dL, the REDUCE-IT profile; preferably with a pure-EPA product, in coordination with the treating cardiologist.
• Peri- and postmenopausal women with rising triglycerides, an inflammatory profile or a low Omega-3 Index.
• Pregnancy and lactation, DHA ≥ 200 to 300 mg/day for neurodevelopment and reduction of preterm-birth risk.
• Depressive symptomatology as an adjunctive strategy using a high-EPA formulation.

Cautions and interactions: a mild antiplatelet effect, clinically insignificant at usual doses, but assessed in combination with anticoagulants or dual antiplatelet therapy and before surgery (high doses discontinued 1 to 2 weeks pre-operatively, case by case). Atrial fibrillation: vigilance at doses ≥ 2 g/day with a history of arrhythmia. Fish allergy: select an algal formulation.

In what form, and at what dosage?

Chemical form determines absorption: re-esterified triglycerides (rTG) show up to ~70% higher bioavailability than ethyl esters (EE), whose absorption depends strongly on co-ingestion of fat. Quality criteria: declared EPA/DHA content per capsule (not "fish oil 1000 mg"), a TOTOX oxidation value under 26 (ideally under 10), and third-party purity certification (IFOS, GOED). Algal oil is an equivalent source of DHA with or without EPA for vegetarians. Always taken with the main meal of the day.

Incorporation into erythrocyte phospholipids is slow: the Omega-3 Index stabilises over 3 to 4 months, whereas triglycerides respond faster, within 4 to 8 weeks.

How do I estimate the result?

• Omega-3 Index: the most reliable marker, the percentage of EPA+DHA in erythrocyte membrane phospholipids, measurable from a finger-prick sample (for example OmegaQuant). Target ≥ 8%; measure at baseline and re-test at 4 months, adjusting the dose accordingly.
• Lipid panel: fasting triglycerides at 8 to 12 weeks; at pharmacological doses, also monitor LDL-C (DHA-containing blends may raise it slightly; pure EPA does not).
• Inflammatory markers: hs-CRP as a secondary trend marker within the same blood panel.
• Clinical endpoints by indication: mood scales for adjunctive use in depression; joint symptoms and NSAID requirement in rheumatoid arthritis; wearable data (HRV, resting heart rate) as a complementary trend picture.

Realistic expectation: the biochemical result (index, triglycerides) is near-guaranteed and fully measurable; the cardiovascular benefit is long-term and not subjectively perceptible, which is precisely why objective measurement of the Omega-3 Index is the key to adherence.

Reviewed by Dr. Erietta Galani, MD, PhD in cellular immunology, dual specialty in internal medicine and intensive care, Founder and Medical Lead, minus10med, Athens.
Last reviewed: 13 September 2026

This article is educational and does not replace individual medical advice, diagnosis or treatment.